Resolution of the online meeting of Russian experts on the EMPEROR-REDUCED trial

Autor:	G. P. Arutyunov, A. G. Arutyunov, E. I. Tarlovskaya, A. S. Ametov, N. G. Vinogradova, A. A. Garganeeva, M. G. Glezer, I. V. Zhirov, M. V. Ilyin, N. A. Koziolova, A. O. Konradi, A. Yu. Lebedeva, Yu. M. Lopatin, S. V. Nedogoda, V. V. Salukhov, M. Yu. Sitnikova, S. N. Tereshchenko, S. N. Tolstov, Yu. Sh. Khalimov, N. R. Khasanov, A. I. Chesnikova, V. Giga, M. Paсker
Jazyk:	ruština
Rok vydání:	2020
Předmět:	empagliflozin heart failure cardiovascular mortality chronic kidney disease emperor-reduced trial Diseases of the circulatory (Cardiovascular) system RC666-701
Zdroj:	Российский кардиологический журнал, Vol 25, Iss 11 (2020)
Druh dokumentu:	article
ISSN:	1560-4071 2618-7620
DOI:	10.15829/29/1560-4071-2020-4167
Popis:	At the online meeting held on September 3, 2020, the results of the international multicenter trial EMPEROR-REDUCED were considered. Number of proposals and recommendations for the further study of cardiovascular and renal effects of empagliflozin and its practical use in heart failure patients were agreed.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/a3a3f78f9f8848ac8a0840a2dddb6e4c Zobrazit plný text záznamu View record in DOAJ